

## Case-report with clinical data of Episealer patient published

A peer-reviewed report from a case-study with clinical data of an Episealer patient has been published in the Journal of Exercise, Sports and Orthopedics.

The study documents how a patient sustained a sporting injury that severely damaged a zone of knee cartilage and ultimately led to several failed surgeries and two years of unemployment. At the age of 31, the patient underwent Episealer surgery, recovered quickly from the procedure and returned to work as a carpenter within three months. Now, more than three years since the Episealer surgery, the patient continues to demonstrate significant pain and outcome score improvements that have also enabled a return to sporting activities.

“This patient has, after many years of severe pain and inability to work, returned to an active life. What is very satisfactory is that the life quality increased significantly, and that the good results do not deteriorate during these three years. It is also interesting that the case report mentions the wider welfare savings that can potentially be offered by our technology, enabling patients to get back to work,” comments Prof. Leif Ryd, Senior Medical Advisor to Episurf Medical.

### **For more information, please contact:**

Pål Ryfors, CEO, Episurf Medical

Tel: +46 (0) 709 62 36 69

Email: [pal.ryfors@episurf.com](mailto:pal.ryfors@episurf.com)

### **About Episurf Medical**

*Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical's Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical's µFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: [www.episurf.com](http://www.episurf.com).*

Case-report with clinical data of Episealer patient published